<DOC>
	<DOCNO>NCT02754479</DOCNO>
	<brief_summary>To evaluate safety effectiveness Excel V system treatment low extremity spider vein ankle .</brief_summary>
	<brief_title>A Clinical Evaluation Treatment Spider Veins Ankles</brief_title>
	<detailed_description>The purpose study evaluate real-world effectiveness 532 nm KTP 1064 nm Nd : YAG laser within Cutera Excel V system treatment low extremity spider vein , specifically ankle , within clinic setting .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<criteria>1 . Males female , 20 75 year age ( inclusive ) . 2 . Fitzpatrick Skin Type I III . 3 . Having spider vein least 1 ankle measure 2.0mm less diameter , linear branching , red , pink , blue and/or purple color , assess investigator . 4 . Having spider vein ankle appropriate laser treatment , assess investigator . 5 . Subject must able read , understand sign Informed Consent Form . 6 . Subject must willing able adhere treatment followup schedule posttreatment care instruction . 7 . Wiling limited sun exposure duration study , include followup period . 8 . Willingness digital photograph take ankle spider vein agree use photograph presentation , educational marketing purpose . 9 . Agree undergo procedure treatment ankle spider vein study . 1 . Fitzpatrick Skin Type IV VI . 2 . Pregnant . 3 . Having infection , dermatitis rash treatment area . 4 . Having significant varicosity perforator vein . 5 . History pigmentary disorder , particularly tendency hyper hypopigmentation . 6 . Systemic use isotretinoin ( AccutaneÂ® ) within 6 month study participation . 7 . Excessively tanned area treat unable/unlikely refrain tan study . 8 . In opinion investigator , physical mental condition might make unsafe subject participate study require systemic therapy could interfere research study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>